Calculators and Tools for Hypertension

ACC/AHA 2017 blood pressure categories: Normal <120/<80 mmHg; Elevated 120–129/<80 mmHg; Stage 1 Hypertension 130–139/80–89 mmHg; Stage 2 Hypertension ≥140/≥90 mmHg; Hypertensive Crisis >180/>120 mmHg (requires immediate evaluation). This classification lowered the hypertension threshold from 140/90 to 130/80, significantly expanding the number of adults classified as hypertensive. Note: ESC/ESH 2023 guidelines retain 140/90 as the treatment threshold — the definition differs internationally.

ACC/AHA guidelines: Start medication at Stage 1 (130–139/80–89) if 10-year ASCVD risk ≥10% or established CVD, CKD, diabetes, or heart failure. For Stage 1 without these, lifestyle modification for 3–6 months first. Start medication at Stage 2 (≥140/≥90) for all patients, usually with two-drug combination. ESC/ESH 2023 recommends starting medication at ≥140/90 for most, ≥130/80 for high-risk patients. First-line agents: ACE inhibitors/ARBs, calcium channel blockers, or thiazide diuretics — all equivalent for most patients.

MAP = [SBP + (2 × DBP)] ÷ 3. It represents the average perfusion pressure throughout the cardiac cycle. Normal MAP: 70–100 mmHg. MAP <65 mmHg indicates inadequate organ perfusion — used as a critical threshold in septic shock and critically ill patients. In chronic hypertension, MAP reflects long-term vascular load and correlates with end-organ damage more strongly than SBP or DBP alone. In patients with TBI, a MAP target ≥80 mmHg is often specified to maintain cerebral perfusion pressure.

Hypertension is the leading modifiable risk factor for cardiovascular disease, contributing to coronary artery disease, stroke, heart failure, and atrial fibrillation. Each 20 mmHg increase in SBP or 10 mmHg increase in DBP doubles CVD risk. The Framingham Risk Score and ASCVD Pooled Cohort Equations incorporate blood pressure as a major variable. Effective BP reduction lowers stroke risk by ~35–40%, MI risk by ~20–25%, and heart failure by ~50%. The SPRINT trial demonstrated that intensive SBP target <120 mmHg reduced cardiovascular events by 25% vs <140 mmHg in high-risk patients.

Hypertensive nephrosclerosis is the second most common cause of CKD in developed countries. Sustained elevated BP damages glomerular capillaries, leading to progressive decline in eGFR and proteinuria. Target BP in CKD: <130/80 mmHg (ADA, KDIGO 2024). ACE inhibitors or ARBs are preferred in CKD with proteinuria (urine ACR >30 mg/g) — they reduce intraglomerular pressure beyond BP lowering. Monitor eGFR 1–2 weeks after starting ACE/ARB (an initial rise in creatinine up to 30% is acceptable and does not require stopping the medication).

Evidence-based lifestyle interventions with approximate SBP reductions: DASH diet (−11 mmHg), sodium restriction to <1500 mg/day (−5–6 mmHg), aerobic exercise 90–150 min/week (−5–8 mmHg), weight loss per 5 kg lost (−4–5 mmHg), limiting alcohol to ≤1 drink/day (−4 mmHg). Combining all interventions can reduce SBP by 20–30 mmHg — sufficient to avoid medication in Stage 1 hypertension in many patients. These measures also enhance the efficacy of antihypertensive medication when both are used together.